TICKERNERD
Menu
LONAHealthcare · Biotechnology

LONA Stock Forecast: LeonaBio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$6.92
+0.87% on the day

The 4 Wall Street analysts covering LeonaBio, Inc. hold a median 12-month price target of $17 — +145.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 10 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$64.6M
Ticker Nerd rank
39 / 100
Median analyst target
$17
Analysts covering
4
Revenue$0.0
Operating income−$19.3M
Net income−$19.0M
Free cash flow−$17.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.1%
1M
−9.2%
YTD
−8.6%
1Y
+81.2%
From 52W high
−40.8%
From 52W low
+92.2%
$4
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LONA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LeonaBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Size
80
Momentum
72
Revisions
45
Volatility
44
Issuance
39
Growth
23
Value
22
Quality
18

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LONA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LONA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26LONAHigh $20Median $17Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $15Median $17High $20

The green dot is the last close — the median target sits +145.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
19 Aug 2026MizuhoMaintainsOutperform$16 → $15
17 Aug 2026CitizensMaintainsMarket Outperform$18 → $17
30 July 2026CitizensUpgradeMarket Outperform$18
30 July 2026CitizensUpgradeMarket Outperform—
27 May 2026Piper SandlerInitiatesOverweight$20
27 May 2026Piper SandlerInitiatesOverweight—
19 Feb 2026MizuhoUpgradeOutperform—
19 Sept 2024MizuhoDowngradeNeutral$5.00 → $0.50
4 Sept 2024BTIGDowngradeNeutral—
4 Sept 2024JMP SecuritiesDowngradeMarket Perform—
19 Aug 2024Rodman & RenshawInitiatesBuy$22
20 June 2024JMP SecuritiesReiteratesMarket Outperform$19
16 May 2024JMP SecuritiesReiteratesMarket Outperform$19
11 Aug 2023JMP SecuritiesMaintainsOutperform$20 → $19
15 May 2023MizuhoMaintainsBuy$6.00 → $5.00
30 Mar 2023BTIGMaintainsBuy$33 → $10
24 Mar 2023JMP SecuritiesReiteratesMarket Outperform$20
7 July 2022MizuhoInitiatesBuy$6.00
23 June 2022JefferiesDowngradeHold$32 → $3.00
23 June 2022JMP SecuritiesDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LONA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LONA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, LeonaBio, Inc. returned +81.2% against +17.5% for the S&P 500, dividends included.

LONA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26LONAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LONA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

LeonaBio, Inc. (LONA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
−0.3×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−431.4%

Higher than 4% of US stocks

Return on assets
−74.1%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

LeonaBio, Inc. (LONA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LeonaBio, Inc. has a market value of $64.6M and an enterprise value of $15.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$141.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$61.9M.

  • Shares outstanding: 9.4M.

  • Trailing P/E: −0.3×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • LeonaBio, Inc. employs 19 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

LONA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LONALeonaBio, Inc.$64.6M
39
DWTXDogwood Therapeutics, Inc.$63.9M
36
BOLDBoundless Bio, Inc.$63.6M
84
SERSerina Therapeutics, Inc.$63.5M
19
SPROSpero Therapeutics, Inc.$63.1M
82
EDSAEdesa Biotech, Inc.$63.0M
53
ELOXEloxx Pharmaceuticals, Inc.$65.7M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LeonaBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LONA news & analysis

LeonaBio to Participate in Cantor Global Healthcare Conference 2026

GlobeNewsWire · 3 Sept 2026neutral

LeonaBio, Inc. announced that its management will participate in the Cantor Global Healthcare Conference 2026, scheduled for September 9-11, 2026 in New York, NY. The company is a clinical-stage biopharmaceutical firm developing novel therapeutics for diseases with high unmet medical needs.

Why it matters — A LONA watcher would care because the company's participation indicates management will be engaging with the investment community at a major industry conference, potentially raising visibility for the company.

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026positive

LeonaBio reported its second quarter 2026 financial results and provided a business update, noting it remains on track to complete enrollment of the Phase 3 ELAINE-3 clinical trial of lasofoxifene in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer in the fourth quarter of 2026, with topline data expected in the second half of 2027.

Why it matters — A LONA watcher would care because the ELAINE-3 trial timeline represents the company's key late-stage pipeline milestone, and the updated guidance signals continued progress toward a potential regulatory catalyst.

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer

GlobeNewsWire · 12 Aug 2026positive

LeonaBio, Inc. announced that its lead product candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology's 4th Summit on Breast Cancer, held August 18–22, 2026, in Kona, Hawaii. The presentations relate to lasofoxifene's use in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

Why it matters — A LONA watcher would care because this gives the company's lead candidate, lasofoxifene, increased clinical visibility and presentation slots at a specialty breast-cancer conference.

FAQ

Frequently asked questions about LONA stock

What is the LONA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering LeonaBio, Inc. have a median 12-month price target of $17, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LONA stock a buy right now?

Of the 4 analysts covering LeonaBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeonaBio, Inc. 39 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LONA?

As at 10 Sept 2026, LeonaBio, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will LONA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +145.7% from the last close, and Ticker Nerd's factor model ranks LeonaBio, Inc. 39 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LONA stock forecast for 2030?

No analyst covering LeonaBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LONA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has LONA stock performed over the past year?

LeonaBio, Inc. returned +81.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LeonaBio, Inc. do?

LeonaBio, Inc. Common Stock represents the equity of LeonaBio, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs.

What is the latest news on LONA?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "LeonaBio to Participate in Cantor Global Healthcare Conference 2026". LeonaBio, Inc. announced that its management will participate in the Cantor Global Healthcare Conference 2026, scheduled for September 9-11, 2026 in New York, NY. The company is a clinical-stage biopharmaceutical firm developing novel therapeutics for diseases with high unmet medical needs.

Company

About LeonaBio, Inc.

LeonaBio, Inc. Common Stock represents the equity of LeonaBio, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs. The company’s current pipeline centers on small-molecule treatments designed to restore neuronal health and address neurodegenerative conditions, including amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease, as well as programs in oncology such as treatment-resistant metastatic breast cancer. LeonaBio also works on therapies for related neurological and neuropathic disorders, with several candidates in clinical development and early-stage research. Headquartered in Bothell, Washington, LeonaBio serves the biotechnology market through a portfolio aimed at advancing drug candidates from preclinical studies into human trials, making its common stock a way to track a company positioned at the intersection of neuroscience and precision therapeutics.

CEO Dr. Mark J. Litton M.B.A., Ph.D. · 19 employees · United States · https://www.leonabio.com